ERBB2 and breast cancer: In a study conducted to demonstrate the clinical significance of HER2+ tumor-infiltrating immune-cells in HER2+ BC patients receiving trastuzumab-based primary systemic therapy (PST), it was revealed that via trogocytosis HER2 can be transferred from BC cells to monocytes and natural killer (NK) cells (Suzuki et al., 2015).